Dimethyl fumarate

Generic Name: Dimethyl fumarate

Brand Names: Tecfidera, Skilarence, Dimethyl fumarate Neuraxpharm, Dimethyl fumarate Mylan, Dimethyl fumarate Accord

Drug Type: Small Molecule

Chemical Formula: C_₆H_₈O_₄

CAS Number: 624-49-7

Unique Ingredient Identifier: FO2303MNI2

Background: Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera, and it was the third oral disease-modifying agent for multiple sclerosis approved by the FDA, following fingolimod and teriflunomide. Prior to its FDA approval, dimethyl fumarate had been used in Germany for treatment of psoriasis.

Indication: Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Associated Conditions: Clinically Isolated Syndrome (CIS), Relapsing Forms of MS, Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)

Clinical Trials

Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke

Phase 2

Withdrawn

Conditions: Acute Ischemic Stroke

Interventions: Drug: Placebo
Drug: Dimethyl Fumarate

First Posted Date: 2021-05-18

Last Posted Date: 2023-10-25

Lead Sponsor: Xuanwu Hospital, Beijing

Registration Number: NCT04891497

Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera

Completed

Conditions: Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Dimethyl fumarate

First Posted Date: 2021-02-16

Last Posted Date: 2023-10-23

Lead Sponsor: Biogen

Target Recruit Count: 1507

Registration Number: NCT04756687

Locations: 🇫🇷
Research Site, Île-de-France - Salpêtrière, France

Relationship Between Oral DMT Burden and Adherence in MS

Conditions: Multiple Sclerosis
Adherence, Medication

Interventions: Drug: Cladribine
Drug: Fingolimod
Drug: Ozanimod
Drug: Dimethyl fumarate
Drug: Teriflunomide
Drug: Diroximel fumarate

First Posted Date: 2020-12-19

Last Posted Date: 2022-08-31

Lead Sponsor: Monash University

Target Recruit Count: 323

Registration Number: NCT04676204

Locations: 🇦🇺
Monash University, Melbourne, Victoria, Australia

Randomised Evaluation of COVID-19 Therapy

Phase 3

Recruiting

Conditions: Severe Acute Respiratory Syndrome

Interventions: Drug: Lopinavir-Ritonavir
Biological: Convalescent plasma
Biological: Immunoglobulin
Drug: Corticosteroid
Drug: Synthetic neutralising antibodies
Drug: Empagliflozin
Drug: Anakinra
Drug: High Dose Corticosteroid
Drug: Sotrovimab
Drug: Paxlovid
Drug: Baloxavir Marboxil
Drug: Hydroxychloroquine
Drug: Azithromycin
Drug: Tocilizumab
Drug: Aspirin
Drug: Dimethyl fumarate
Drug: Colchicine
Drug: Baricitinib
Drug: Oseltamivir
Drug: Molnupiravir

First Posted Date: 2020-05-11

Last Posted Date: 2024-01-05

Lead Sponsor: University of Oxford

Target Recruit Count: 70000

Registration Number: NCT04381936

Locations: 🇻🇳
Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
🇬🇭
Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana
🇮🇳
Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India

and more 4 locations